Bjoern Papke
Cited by
Cited by
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
G Zimmermann, B Papke, S Ismail, N Vartak, A Chandra, M Hoffmann, ...
Nature 497 (7451), 638-642, 2013
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 25 (4), 628-640, 2019
Drugging RAS: Know the enemy
B Papke, CJ Der
Science 355 (6330), 1158-1163, 2017
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport
M Schmick, N Vartak, B Papke, M Kovacevic, DC Truxius, L Rossmannek, ...
Cell 157 (2), 459-471, 2014
Identification of pyrazolopyridazinones as PDEδ inhibitors
B Papke, S Murarka, HA Vogel, P MartÝn-Gago, M Kovacevic, DC Truxius, ...
Nature communications 7 (1), 11360, 2016
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ...
Cancer discovery 10 (1), 104-123, 2020
The autodepalmitoylating activity of APT maintains the spatial organization of palmitoylated membrane proteins
N Vartak, B Papke, HE Grecco, L Rossmannek, H Waldmann, C Hedberg, ...
Biophysical journal 106 (1), 93-105, 2014
Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers
I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ...
Cell reports 31 (11), 2020
Precise measurement of protein interacting fractions with fluorescence lifetime imaging microscopy
KA Walther, B Papke, MB Sinn, K Michel, A Kinkhabwala
Molecular Biosystems 7 (2), 322-336, 2011
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ...
Cancer research 83 (1), 141-157, 2023
Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors
CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ...
Cancer research 82 (4), 586-598, 2022
Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ...
Cell reports 35 (13), 2021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ...
Cell reports 37 (9), 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ...
Journal of Biological Chemistry 297 (5), 2021
Silencing of oncogenic KRAS by mutant-selective small interfering RNA
B Papke, SH Azam, AY Feng, C Gutierrez-Ford, H Huggins, PS Pallan, ...
ACS Pharmacology & Translational Science 4 (2), 703-712, 2021
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 26 (6), 982-982, 2020
Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer
CM Goodwin, S Javaid, AM Waters, B Papke, R Yang, M Pierobon, ...
Cancer Research 79 (13_Supplement), LB-287-LB-287, 2019
the spatial organization of Ras signaling
B Papke, M Schmick, N Vartak, PIH Bastiaens
Ras Superfamily Small G Proteins: Biology and Mechanisms 1: General Featuresá…, 2014
Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA
B Papke, AED Van Swearingen, AY Feng, SH Azam, EB Harrison, R Yang, ...
Molecular Cancer Research 18 (5_Supplement), B32-B32, 2020
Eine neue ─ra der Tumortherapie: RAS-Proteine als pharmakologische Targets
B Papke, C Sers
PHARMAKON 12 (2), 114-120, 2024
The system can't perform the operation now. Try again later.
Articles 1–20